How many insider trades does FilingIQ track for SPRO?

FilingIQ tracks 197 Form 4 insider transactions for SPRO (Spero Therapeutics, Inc.), covering filings from Dec 13, 2017 onwards. 1 of those were filed in the last 90 days.

Are SPRO insiders net buyers or net sellers?

Across the full Form 4 history for SPRO, 28 transactions (14%) were open-market purchases and 81 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SPRO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SPRO in?

Spero Therapeutics, Inc. (SPRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $146.49M.

SPRO insider trading

NasdaqGS Healthcare

Spero Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

197

Last 90 days

Buys / sells

14% / 41%

Market cap

$146.49M

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Company website: sperotherapeutics.com

SPRO insider activity at a glance

FilingIQ has scored 197 insider transactions for SPRO since Dec 13, 2017. The most recent filing in our index is dated May 4, 2026.

Across the full history, 28 open-market purchases and 81 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SPRO insider trades is 48.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SPRO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for SPRO?: FilingIQ tracks 197 Form 4 insider transactions for SPRO (Spero Therapeutics, Inc.), covering filings from Dec 13, 2017 onwards. 1 of those were filed in the last 90 days.
Are SPRO insiders net buyers or net sellers?: Across the full Form 4 history for SPRO, 28 transactions (14%) were open-market purchases and 81 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SPRO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SPRO in?: Spero Therapeutics, Inc. (SPRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $146.49M.

Methodology & sources

Every SPRO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.